Prediction: This Is Where Pfizer Stock Will Be in 2030

Pfizer faces significant patent expirations for major drugs (Ibrance, Xtandi, and Eliquis) between 2027-2028, which is pressuring its stock valuation and causing investor concern. However, the company is expected to recover by 2030 through new drug development and acquisitions, with management predicting high-single-digit revenue growth post-2028. While the company maintains an attractive 6.4% dividend yield, ongoing patent cliff risks remain a structural challenge for the business.